Literature DB >> 17355420

Evidence-based veterinary dermatology: a systematic review of interventions for treatment of Pseudomonas otitis in dogs.

Tim Nuttall1, Lynette K Cole.   

Abstract

The efficacy and safety of pharmacological interventions to treat canine Pseudomonas otitis externa and media were evaluated based on the systematic review of clinical trials published between 1967 and 2006. Clinical trials were included if Pseudomonas species were cultured from the ears of dogs with otitis externa or otitis media prior to treatment, and if the outcome of these interventions was reported at the end of the study. Studies were compared with regard to design characteristics (randomization generation and concealment, masking, intention-to-treat analyses), benefit (microbiological and/or clinical resolution of the Pseudomonas otitis), and adverse effects. Ten trials reporting data on 162 patients and 13 different pharmacological interventions were identified. Based on the accepted criteria for quality of evidence, there is insufficient evidence for or against recommending the use of any of these treatments for Pseudomonas otitis in dogs. This is largely because there is only one trial supporting the use of each treatment option and none were randomized controlled trials. Future studies need to be prospective, randomized, blinded and controlled; designed to evaluate pharmacological interventions for otitis regardless of the infective organism; have appropriate statistical advice on recruitment numbers, the power of the study and appropriate statistical analysis; include details of underlying conditions and concomitant treatments; and be designed such that inclusion criteria include microbial culture and antimicrobial sensitivity, and outcome assessments include clinical examination, cytology and microbial culture.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17355420     DOI: 10.1111/j.1365-3164.2007.00575.x

Source DB:  PubMed          Journal:  Vet Dermatol        ISSN: 0959-4493            Impact factor:   1.589


  6 in total

1.  Effective treatment and decolonization of a dog infected with carbapenemase (VIM-2)-producing Pseudomonas aeruginosa using probiotic and photodynamic therapies.

Authors:  Fábio P Sellera; Miriam R Fernandes; Caetano P Sabino; Laura M de Freitas; Luciano C B A da Silva; Fabio C Pogliani; Martha S Ribeiro; Michael R Hamblin; Nilton Lincopan
Journal:  Vet Dermatol       Date:  2019-01-03       Impact factor: 1.589

2.  A randomized placebo-controlled trial of the efficacy and safety of a terbinafine, florfenicol and betamethasone topical ear formulation in dogs for the treatment of bacterial and/or fungal otitis externa.

Authors:  S L Forster; T Real; K P Doucette; S B King
Journal:  BMC Vet Res       Date:  2018-08-31       Impact factor: 2.741

Review 3.  Hospital-associated infections in small animal practice.

Authors:  Jason W Stull; J Scott Weese
Journal:  Vet Clin North Am Small Anim Pract       Date:  2015-01-02       Impact factor: 2.093

4.  Effect of an ear cleaner instillation containing lipacids in a model of re-acidification of the external auditory canal in dogs.

Authors:  Pauline Panzuti; Marion Mosca; Oscar Fantini; Guillaume Noel; Julien Cappelle; Didier Pin
Journal:  Vet Dermatol       Date:  2022-07-06       Impact factor: 1.867

5.  Determination of N-acylhomoserine lactones of Pseudomonas aeruginosa in clinical samples from dogs with otitis externa.

Authors:  Darja Kušar; Karin Šrimpf; Petra Isaković; Lina Kalšek; Javid Hosseini; Irena Zdovc; Tina Kotnik; Modest Vengušt; Gabrijela Tavčar-Kalcher
Journal:  BMC Vet Res       Date:  2016-10-18       Impact factor: 2.741

6.  A randomized, controlled, single-blinded, multicenter evaluation of the efficacy and safety of a once weekly two dose otic gel containing florfenicol, terbinafine and betamethasone administered for the treatment of canine otitis externa.

Authors:  S B King; K P Doucette; W Seewald; S L Forster
Journal:  BMC Vet Res       Date:  2018-10-11       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.